Stocks · Health care · Pharmaceutical Preparations

Evolus, Inc.

EOLS Clue Score45
United States Fiscal year ends December CIK 0001570562 Results filed 4 Nov 2026

What the insiders did Net selling

By person

11 insiders · 7 transactions
5.8×

David Moatazedi holds 5.8 times base salary in stock. $4.52M of shares against $775.00K in salary for 2025.

Salary from the company's own proxy. The shares are what David Moatazedi last reported holding, valued at $9.04, the price Common Stock was last bought or sold at on the open market here, on 2 Sep 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
David Moatazedi
See Remarks
—
$1.66M (4)
−$1.66M
499,592
0.7564%
$4.52M
−6.3%
Rui Avelar
See Remarks
—
$177.61K (3) scheduled
−$177.61K
427,423
0.6471%
$3.86M
+15.9%
Vikram Malik
Director
—
—
—
321,109
0.4862%
$2.90M
+19.7%
Tatjana Mitchell
Chief Financial Officer
—
—
—
226,092
0.3423%
$2.04M
—
Sandra Beaver
Chief Financial Officer
—
—
—
167,089
0.2530%
$1.51M
+12.5%
Brady Stewart
Director
—
—
—
134,188
0.2032%
$1.21M
+161.8%
Albert G White III
Director
—
—
—
95,937
0.1452%
$867.13K
+316.9%
Tomoko Yamagishi-Dressler
Chief Marketing Officer
—
—
—
89,949
0.1362%
$813.00K
+9.2%
David N Gill
Director
—
—
—
86,887
0.1315%
$785.33K
+155.8%
Karah Herdman Parschauer
Director
—
—
—
77,742
0.1177%
$702.67K
+106.2%
Simone Blank
Director
—
—
—
77,111
0.1167%
$696.97K
+10.6%